552 Stadler,M et al Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT . British Journal of Haematology (2019);184: 782–787 [11] Schmid C, Labopin M , Schaap N, Veelken H , Brecht A, Stadler M et al Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia Bone Marrow Transplantation (2022) 57:215–223 [12] Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood (2010) 116:3572-3518 [13] Jurdi N , Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B et al Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies Immunotherapy (2013);5(5):457-66. [14] Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A,Mielke S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT Haematologica 2020 Volume 105(1):47-58 [15] Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signosi A, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mis- matched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29(5):1143-1152. [16] Miyamoto T, Fukuda T, Nakashima M, Henzan T, Kusakabe S, Kobayashi N et al. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program Biol Blood Marrow Transplant (2017); 23: 938–944. [17] Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H et al. Comparison of outcomes after donor lymphocyte infusion with and without prior chemotherapy for minimal residual disease in acute leukemia/myelodisplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology (2017); 96:829-838. [18] Schroeder T, Rautenberg C, Krueger W, Platzbecker U, Bug G, Steinmann J, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Annals of Hematology (2018);97: 335–342. [19] Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, et al Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leukemia research (2018); 72: 20-26. [20] Shanavas M , Messner HA , Kamel-Reid S , Atenafu EG, Gupta V , Kuruvilla J et al A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation Clin Lymphoma Myeloma Leuk (2014);14:87-92. [21] Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood (2011);118:2413-9 [22] Kröger N , Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A et al, Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients Bone Marrow Transplant. (2013) 48:403-7. [23] Montefusco V , Spina F, Patriarca F, Offidani M, Bruno B, Montanari M et al Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation Biol Blood Marrow Transplant. (2013); 19:424-8. [24] Xin LI SC, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. International Journal of Hematology (2004); 79:178-184. [25] Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, et al Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data. J Hematology & Oncology (2020); 13: 2-11 [26] Gao XN, Lin J, Wang LJ,Li F, Li HH, Wang SH, et al Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Annals of Hematology (2019); 98: 1267–1277. [27] Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, et al. Phase 1 clinical trial using mbIL21 ex vivo-expand- ed donor-derived NK cells after haploidenti- cal transplantation. Blood. 2017;130(16); 1857-1868. [28] Roy D-C, Walker I, Maertens J, Lewalle P, Olavarria E, Beguin Y, et al. Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T- Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two-Phase II Studies. Blood. 2018;132 (Suppl 1):120. [29] Merli P, Bertaina V, Galaverna F, et al. Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post- Allograft Infusion in Patients Given αβ T- Cell and B-Cell Depleted HLA- Haploidentical Allogeneic Stem Cell Transplantation (αβ haplo-HSCT) Contributing to Accelerate Immune Recovery. Blood. 2017;130(Suppl 1):211. [30] Frey NV, Porter DL. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol (2008); 21:205–22. [31] Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, et al. A multi- centre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant (2015);50:62–7. [32] Yu WY, Mo XD , Zhang XH, Xu LP, Wang Y, Yan CH et al. Occurrence and Severity of Donor Lymphocyte Infusion_Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Biol Blood Marrow Transplant 25 (2019) 912-920 [33] Keil F , Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood (1997); 89(9):3113-7.
RkJQdWJsaXNoZXIy ODUzNzk5